IgG4相关疾病

别名

免疫球蛋白G4相关硬化性疾病

基本事实

遗传方式

不适用

发病年龄

成年期

近两年的全球研究 1,897L2

2024/10 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。

• 2026-11开放获取
  PSC-DM: A Validated Clinical Diagnostic Model for Distinguishing Primary From Secondary Sclerosing Cholangitis
  Liver international : official journal of the International Associatio · DOI · Europe PMC
• 2026-10开放获取
  IgG4-to-IgG Ratio and Orbital Involvement Predict Clinical Response to B Cell Depletion in IgG4-Related Disease
  ACR open rheumatology · DOI · Europe PMC
• 2026-09开放获取
  A Retrospective Review of 1821 Cases of Eosinophilia in a Single-Center Study in Eastern China
  EJHaem · DOI · Europe PMC
• 2026-09病例报告开放获取
  When seizure control comes at a cost: valproic acid-induced necrotising pancreatitis in a patient receiving antiepileptic polypharmacy
  BMJ case reports · DOI · Europe PMC
• 2026-09开放获取
  Eosinophilic Sialodochitis Identified in Duct Remnant After Submandibular Gland Resection
  World journal of otorhinolaryngology - head and neck surgery · DOI · Europe PMC
• 2026-09
  Delayed and multisystem immune-related adverse events in MSI-high colon cancer treated with nivolumab plus ipilimumab
  Clinical journal of gastroenterology · DOI · Europe PMC
• 2026-09开放获取
  Rheumatologists' expectations and perceptions of T-cell redirecting therapies: results from a cross-sectional survey
  Rheumatology international · DOI · Europe PMC
• 2026-09
  Isolated pulmonary IgG4-related disease mimicking infection and malignancy: clinical features and a proposed diagnostic approach
  Clinical rheumatology · DOI · Europe PMC
• 2026-09病例报告开放获取
  A case report: an unusual case of ulcerative intestinal IgG4-related disease with clinical features overlapping with probable intestinal Behcet's disease
  BMC gastroenterology · DOI · Europe PMC
• 2026-09开放获取
  SCTS Annual Meeting 2025: Abstracts
  Journal of cardiothoracic surgery · DOI · Europe PMC
• 2026-09病例报告
  Cutaneous IgG4-Related Disease Accompanied by Granulomatous Vasculitis: A Case Report
  Journal of cutaneous pathology · DOI · Europe PMC
• 2026-09综述
  Fibroblast Activation Protein-Directed PET: Expanding FAPI Beyond Cancer
  AJR. American journal of roentgenology · DOI · Europe PMC
• 2026-09
  Orbital granulomatosis with polyangiitis: MRI discriminators from IgG4-related disease and lymphoma
  The British journal of radiology · DOI · Europe PMC
• 2026-09
  Leukopenia and thrombocytopenia in immunoglobulin G4-related disease: frequency, severity, and the association with splenomegaly
  Immunological medicine · DOI · Europe PMC
• 2026-09开放获取
  Sjögren's Disease-Associated Parotid MALT Lymphoma: Diagnostic Pitfall of Ultrasound-Guided Core Needle Biopsy
  Diagnostics (Basel, Switzerland) · DOI · Europe PMC
• 2026-09病例报告开放获取
  Simultaneous Thyroid Eye Disease and IgG4-Related Orbital Disease in a Patient With Diabetes Mellitus: A Case Report
  The American journal of case reports · DOI · Europe PMC
• 2026-09综述开放获取
  Quantitative total serum IgG4 reporting in human paragonimiasis: a scoping review
  Tropical medicine and health · DOI · Europe PMC
• 2026-09
  [A case of IgG4-related pia mater inflammation]
  Rinsho shinkeigaku = Clinical neurology · DOI · Europe PMC
• 2026-09病例报告开放获取
  Diagnostic Reassessment of a Pulmonary Mass Initially Suspected to Represent IgG4-Related Lung Disease: The Complementary Role of Tissue Metagenomic Sequencing
  Diagnostics (Basel, Switzerland) · DOI · Europe PMC
• 2026-09开放获取
  Proceedings of the 33rd European Paediatric Rheumatology Congress
  Pediatric rheumatology online journal · DOI · Europe PMC

境外已获批用于本病的药物 0L2

欧盟与美国均未检索到已获批用于本病的药物。

数据来自欧洲药品管理局（EMA）的药品与罕见病用药资格公开导出表，以及美国 FDA 的罕见病用药资格数据库（Orphan Drug Product Designation Database）。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。

在中国开展的临床试验 41L2

按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。

登记为可入组 20

• 招募中NCT01670695
  A Prospective Cohort Study of IgG4RD in China
  观察性 · 2012/01Peking Union Medical College Hospital
  中国研究中心 1 个：Beijing
• 招募中NCT03023371
  National Registry of IgG4-RD in China
  观察性 · 2016/12Peking Union Medical College Hospital
  中国研究中心 1 个：Beijing
• 招募中NCT05789030
  Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
  不适用 · 干预性 · 2022/07/01Peking Union Medical College Hospital
  中国研究中心 1 个：Beijing
• 招募中NCT06663618
  Short-term Glucocorticoid Combined with MMF for IgG4-RD
  不适用 · 干预性 · 2023/09/01Wen Zhang
  中国研究中心 1 个：Beijing
• 招募中NCT06285279
  The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
  I 期 · 干预性 · 2024/03/04Nanjing University School of Medicine
  中国研究中心 1 个：Nanjing
• 招募中NCT06497387
  Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
  早期 I 期 · 干预性 · 2024/07Tongji Hospital
  中国研究中心 1 个：Wuhan
• 招募中NCT06497361
  Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
  早期 I 期 · 干预性 · 2024/07Tongji Hospital
  中国研究中心 1 个：Wuhan
• 招募中NCT06794008
  BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
  II 期 · 干预性 · 2024/12/26Peking University People's Hospital
  中国研究中心 1 个：Beijing
• 尚未开始招募NCT06978738
  UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
  I 期 · 干预性 · 2025/05Changzhou No.2 People's Hospital
  中国研究中心 1 个：Changzhou
• 招募中NCT07104058
  A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
  不适用 · 干预性 · 2025/05/10Luo Yaping
  中国研究中心 1 个：Beijing
• 招募中NCT06978647
  A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
  I 期 · 干预性 · 2025/05/19China Immunotech (Beijing) Biotechnology Co., Ltd.
  中国研究中心 1 个：Beijing
• 招募中NCT07068165
  A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
  II 期、III 期 · 干预性 · 2025/07/07Peking Union Medical College Hospital
  中国研究中心 1 个：Beijing
• 招募中NCT07148791
  Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
  II 期 · 干预性 · 2025/09/05Chinese PLA General Hospital
  中国研究中心 1 个：Beijing
• 招募中NCT07190196
  A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
  III 期 · 干预性 · 2025/09/26Sanofi
  中国研究中心 10 个：Beijing、Chengdu、Hangzhou、Jiazhuang、Taiyuan、Wuhan 等 7 地
• 尚未开始招募NCT07298590
  An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease
  早期 I 期 · 干预性 · 2025/12/30Changhai Hospital
  中国研究中心 1 个：Shanghai
• 尚未开始招募NCT07583030
  A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
  早期 I 期 · 干预性 · 2026/04/20Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  中国研究中心 4 个：Beijing、Hefei、Taiyuan、Wuhan
• 尚未开始招募NCT07593911
  A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
  不适用 · 干预性 · 2026/06Beijing GoBroad Hospital
  中国研究中心 1 个：Beijing
• 尚未开始招募NCT07719543
  Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
  III 期 · 干预性 · 2026/08/01Chinese PLA General Hospital
  中国研究中心 3 个：Beijing、Sanya、Wuhan
• 尚未开始招募NCT07806045
  Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
  早期 I 期 · 干预性 · 2026/10/14Qiubai Li
  中国研究中心 1 个：Beijing
• 尚未开始招募NCT07222553
  Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
  II 期 · 干预性 · 2026/10/31Amgen
  中国研究中心 2 个：Beijing、Changsha

中国境外的在招试验 33L2

CT.gov 报告命中 33 项，此处取回并展示最近的 13 项。

• 尚未开始招募NCT07793903
  BCT301 in Treating Refractory/Recurrent IgG4-related Disease
  不适用 · 干预性 · 2026/10Peking University Third Hospital
• 尚未开始招募NCT07621939
  A Study of IMM0306 in IgG4-Related Disease
  II 期、III 期 · 干预性 · 2026/07ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
• 招募中NCT07536841
  Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis
  观察性 · 2026/05/01Military Medical Clinical Center of the Southern Region, Ukraine
  乌克兰
• 招募中NCT07061938
  Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
  I 期、II 期 · 干预性 · 2026/01/01Acepodia Biotech, Inc.
  日本、美国
• 招募中NCT07535554
  The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.
  II 期、III 期 · 干预性 · 2025/09/17Universitaire Ziekenhuizen KU Leuven
  比利时
• 招募中NCT06696027
  AYLo - AutoimmunitY and Loss of y
  观察性 · 2024/11/15University of Bonn
  德国
• 尚未开始招募NCT06655831
  Key Mechanisms of Abnormal T Cell Activation and Differentiation in IgG4-Related Ophthalmic Disease
  观察性 · 2024/11/01Peking University Third Hospital
• 尚未开始招募NCT06270524
  Study of the C5a/C5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target
  不适用 · 干预性 · 2024/09/01Assistance Publique Hopitaux De Marseille
• 招募中NCT06573723
  Institutional Registry of Rare Diseases
  观察性 · 2024/07/01Hospital Italiano de Buenos Aires
  阿根廷
• 招募中NCT06285539
  Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
  II 期 · 干预性 · 2024/03/12UMC Utrecht
  荷兰
• 尚未开始招募NCT05746689
  Study of Sirolimus in IgG4-related Disease
  不适用 · 干预性 · 2023/03/01Peking University International Hospital
• 招募中NCT03473912
  Meir Medical Center Rheumatologic Biobank
  观察性 · 2018/04/16Meir Medical Center
  以色列
• 招募中NCT05681975
  Immunoglobulin G4 and Immunoglobulin E Antibodies in a Population With Adverse Reactions to Foodstuffs-related Symptoms
  观察性 · 2017/10/01Universidad Politecnica de Madrid
  西班牙

外部标识与链接